Skip to main content
Equibles
CDXS logo

CDXS · Codexis, Inc. · Metrics

Track CDXS — free

Use CDXS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CDXS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.05 -0.03 (-2.78%) Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$118.27M
Shares
109.51M
Volume · Nov 5 871.76K Avg daily vol (3M) 935.69K

CDXS metrics

91 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.02
Market cap
$118.27M

Price action

20 metrics
Price change (1W)
-14.3%
Price change (30D)
-20.6%
Price change (3M)
-25.5%
Price change (6M)
-59.4%
Price change (YTD)
-33.7%
Price change (1Y)
-50.2%
Trailing year
Price change (5Y)
-96.9%
52-week high
$2.85
52-week low
$0.98
Change from 52-week high
-62.1%
Change from 52-week low
+10.2%
Annualized volatility
86.9%
Annualized volatility (3M)
63.7%
Beta
1.9
RSI (14D)
33.3
Price vs SMA 50
-20.9%
Price vs SMA 200
-40.3%
Avg volume (3M)
934,299
Relative volume
0.7
Average dollar volume
$1.33M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
109.51M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.3×
reciprocal yield 74.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 65.7%
P / book
3.6
reciprocal yield 27.9%
FCF yield
-10.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.8×
reciprocal yield 36.0%
EV / revenue historical average (5Y)
4.2×
reciprocal yield 23.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-12
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
87.0%
Operating margin
-35.6%
Trailing 12 months
Net margin
-39.6%
Gross profit (TTM)
$67.59M
Operating profit (TTM)
−$27.66M
Net income (TTM)
−$30.72M
Trailing 12 months
Diluted EPS (TTM)
$-0.32
FCF margin
-15.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.86
Gross profit per diluted share (TTM)
$0.75
Operating profit per diluted share (TTM)
$-0.31
EBITDA per diluted share (TTM)
$-0.25
Net income per diluted share (TTM)
$-0.34
Operating cash flow per diluted share (TTM)
$-0.11
Free cash flow per diluted share (TTM)
$-0.13
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$0.54
Stock compensation per diluted share (TTM)
$0.09
Book value per share
$0.56

Growth

11 metrics
Revenue growth YoY
-2.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$77.68M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.6%
Year over year · more shares
Revenue CAGR (3Y)
-20.2%
Revenue CAGR (5Y)
+0.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-93.2%
Return on assets
-25.6%
Debt / equity
1.2
Current ratio
3.1
EBITDA (TTM)
−$22.45M
Free cash flow (TTM)
−$12.18M
Quick ratio
3.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$14.04M
Latest balance sheet
Cash & equivalents
$27.17M
Total assets
$120.06M
Total debt
$40.88M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.40M
Capital expenditures (TTM)
$1.78M
R&D (TTM)
$48.74M
SG&A (TTM)
$43.11M
Stock compensation (TTM)
$7.72M
R&D / revenue
62.7%
Stock compensation / revenue
9.9%

Ownership (13F)

9 metrics
13F filers
148
13F filer change QoQ
+13
Institutional ownership
59.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
27.2%
Private-fund adviser ownership
23.8%
Active holders' share change QoQ
-0.3%
Holder tenure
15.7
Price vs estimated holder cost
-11.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.3%

Short interest

3 metrics
Short interest
4.5%
Latest settlement · 6.3 days to cover
Days to cover
6.3d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$17,239
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1200375 CUSIP 192005106 13F (30d) 34 filings 34 filers Visit website Investor relations